In partnership with rheumatology and other specialty organizations, the ACR is working against payer and employer policies that mandate specialty pharmacy acquisition of in-office treatments.
Sarilumab Investigated to Treat COVID-19
A study investigating sarilumab’s effects on patients with COVID-19 has begun in New York. The treatment blocks IL-6, which may play a role in the respiratory distress caused by the virus…
2019 MIPS Deadline Extension & Policy Update
CMS has extended the deadline for 2019 MIPS submission to 8 p.m. EDT on April 30, 2020.
Axial Spondyloarthritis & Exercise: Should axSpA Patients Exercise?
Two experts weigh in on whether & how axial spondyloarthritis patients should exercise…
Texas Society & Meeting Provide Professional Value, Advocacy Vision
Hundreds of physicians and practice managers gathered Feb. 28–Mar. 1 in Houston at the annual meeting of the State of Texas Association of Rheumatologists to hear clinical updates, obtain practice management tips and get to know their peers.
New Options Emerge for Treating Macrophage Activation Syndrome
ATLANTA—Macrophage activation syndrome (MAS), a subset of hemophagocytic lymphohistiocytosis (HLH) disease, can be a fatal result of rheumatic disease. But there’s good news: New therapeutic options for refractory MAS targeting individual cytokines are emerging. At the 2019 ACR/ARP Annual Meeting, possible therapeutic options were presented during a pediatric-focused clinical and translational research track, Therapeutic Approaches…
Key Studies Highlighted: 2 Industry Veterans Discuss Their Favorite Annual Meeting Abstracts
ATLANTA—With more than 3,000 abstracts from 103 countries presented at the 2019 ACR/ARP Annual Meeting in November, it was impossible for attendees to view them all. However, two ACR/ARP veterans—Arthur Kavanaugh, MD, from the University of California, San Diego, and John Cush, MD, from UT Southwestern Medical School, Dallas—chose to tackle the nearly impossible task and…
New Research Identifies Possible Preclinical Rheumatoid Arthritis Biomarkers
ATLANTA—A key goal for rheumatology researchers and clinicians is to predict through specific biomarkers if someone will, at some point in their future, develop rheumatoid arthritis (RA). If so, the disease could be prevented or stopped before the inflammation and ravaging begins, explained researchers during a Basic Science lecture at the 2019 ACR/ARP Annual Meeting…
Regeneron Plans Early Summer Trials for New Antibodies Against Coronavirus
(Reuters)—Regeneron Pharmaceuticals Inc. said on Tuesday it had identified hundreds of antibodies that could treat or prevent the coronavirus (COVID-19) and was preparing to begin clinical trials by early summer, sending the drugmaker’s shares up 12%. The company will select the top two antibodies to develop a “cocktail” treatment and scale up its manufacturing to…
HHS Relaxes HIPAA Enforcement
Effective immediately, the HHS Office for Civil Rights (OCR) has stated it will not impose any noncompliance penalties under the Health Insurance Portability and Accountability Act (HIPAA) on physicians using any non-public facing service or audio or video communication technology (e.g., Apple FaceTime, Skype, Facebook Messenger, etc.) for telehealth services. This discretion applies to telehealth…
- « Previous Page
- 1
- …
- 86
- 87
- 88
- 89
- 90
- …
- 309
- Next Page »